Comparison Overview

MACLEODS PHARMACEUTICALS LTD.

VS

Ipca Laboratories Limited

MACLEODS PHARMACEUTICALS LTD.

304, Atlanta Arcade Marol Church Road, Andheri East, Mumbai, Maharashtra, IN, 400059
Last Update: 2025-12-10

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 11,522
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Ipca Laboratories Limited

125 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, IN, 400067
Last Update: 2025-12-09
Between 750 and 799

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,205
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/macleods-pharmaceuticals-ltd..jpeg
MACLEODS PHARMACEUTICALS LTD.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/ipca.jpeg
Ipca Laboratories Limited
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
MACLEODS PHARMACEUTICALS LTD.
100%
Compliance Rate
0/4 Standards Verified
Ipca Laboratories Limited
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MACLEODS PHARMACEUTICALS LTD. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Ipca Laboratories Limited in 2025.

Incident History — MACLEODS PHARMACEUTICALS LTD. (X = Date, Y = Severity)

MACLEODS PHARMACEUTICALS LTD. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Ipca Laboratories Limited (X = Date, Y = Severity)

Ipca Laboratories Limited cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/macleods-pharmaceuticals-ltd..jpeg
MACLEODS PHARMACEUTICALS LTD.
Incidents

No Incident

https://images.rankiteo.com/companyimages/ipca.jpeg
Ipca Laboratories Limited
Incidents

No Incident

FAQ

MACLEODS PHARMACEUTICALS LTD. company demonstrates a stronger AI Cybersecurity Score compared to Ipca Laboratories Limited company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Ipca Laboratories Limited company has disclosed a higher number of cyber incidents compared to MACLEODS PHARMACEUTICALS LTD. company.

In the current year, Ipca Laboratories Limited company and MACLEODS PHARMACEUTICALS LTD. company have not reported any cyber incidents.

Neither Ipca Laboratories Limited company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing a ransomware attack publicly.

Neither Ipca Laboratories Limited company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing a data breach publicly.

Neither Ipca Laboratories Limited company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing targeted cyberattacks publicly.

Neither MACLEODS PHARMACEUTICALS LTD. company nor Ipca Laboratories Limited company has reported experiencing or disclosing vulnerabilities publicly.

Neither MACLEODS PHARMACEUTICALS LTD. nor Ipca Laboratories Limited holds any compliance certifications.

Neither company holds any compliance certifications.

Neither MACLEODS PHARMACEUTICALS LTD. company nor Ipca Laboratories Limited company has publicly disclosed detailed information about the number of their subsidiaries.

Ipca Laboratories Limited company employs more people globally than MACLEODS PHARMACEUTICALS LTD. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither MACLEODS PHARMACEUTICALS LTD. nor Ipca Laboratories Limited holds SOC 2 Type 1 certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor Ipca Laboratories Limited holds SOC 2 Type 2 certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor Ipca Laboratories Limited holds ISO 27001 certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor Ipca Laboratories Limited holds PCI DSS certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor Ipca Laboratories Limited holds HIPAA certification.

Neither MACLEODS PHARMACEUTICALS LTD. nor Ipca Laboratories Limited holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N